

Posterior reversible encephalopathy syndrome (PRES) presenting as Status Epilepticus in a case of Autoimmune Hemolytic Anemia (AIHA): A Case report



Sameera Dronamraju¹, Shilpa Gaidhane², Aayush Somani³, Sourya Acharya⁴

^{1,3}Junior Resident, ⁴Professor and Head, Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (DU), Wardha, India, ²Professor, Department of Medicine, School of Clinical Epidemiology and Public Health, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (DU), Wardha, India

Submission: 27-12-2020

Revision: 26-04-2021

Publication: 01-06-2021

ABSTRACT

Posterior reversible encephalopathy syndrome (PRES) is a neurotoxic state, caused by imbalance in autoregulation of posterior cerebral circulation. We report a case of young female, presented at emergency department with complains of nausea, vomiting and generalized tonic clonic seizures prior to admission. During the course of hospital stay patient landed in status epilepticus which was treated appropriately. Patient's magnetic resonance imaging (MRI) was done which had classical features of vasogenic edema in occipital and parietal region, suggestive of PRES. She was a known case of autoimmune hemolytic anemia that was treated with multiple blood transfusions and low dose oral steroids. She was discharged after complete resolution of symptoms with the advice to follow up in medicine outpatient department. Our case describes about autoimmune hemolytic anemia in which occurrence of PRES is uncommon. Early diagnosis and robust treatment can prevent permanent damage to the brain, and is often associated with complete recovery.

Key words: Posterior Reversible Encephalopathy Syndrome; Hemolytic anemia; Sporadic disease

Access this article online

Website:

<http://nepjol.info/index.php/AJMS>

DOI: 10.3126/ajms.v12i6.33817

E-ISSN: 2091-0576

P-ISSN: 2467-9100

Copyright (c) 2021 Asian Journal of Medical Sciences



This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

INTRODUCTION

Posterior Reversible Encephalopathy Syndrome is a disease of heterogenous etiologies commonly presenting as headache, vomiting, visual disturbances, seizures, and confusion. Acute changes in blood pressure are commonly associated with this.¹ Although PRES is being recognized and reported more often than before, the exact incidence is still unknown. Even though patients of all sexes and age groups are susceptible, it is more commonly seen in women. It is understood that many medical conditions and medicines raise the risk of posterior reversible encephalopathy syndrome.

Autoimmune hemolytic anemia (AIHA) is a disorder marked by presence of autoantibodies that attach to patient's erythrocytes causing hemolysis of red blood cells. AIHA is categorized as warm AIHA (reactive), cold AIHA and paroxysmal hemoglobinuria. AIHA can be either primary (idiopathic) AIHA or secondary AIHA in association with other systemic illnesses.

In a female patient with autoimmune hemolytic anemia, we report a rare case of posterior reversible encephalopathy syndrome.

Address for Correspondence:

Dr. Shilpa Gaidhane, Department of Medicine, School of Clinical Epidemiology and Public Health, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (DU), Wardha, India. **Mobile:** +91-9673288822. **E-mail:** dr.shilpagaidhane@gmail.com

CASE PRESENTATION

Patient information

We present a case of 23-year-old female, a known case of Autoimmune Hemolytic Anemia diagnosed 1 month back. She came to our tertiary care hospital in emergency department with history of headache, nausea, vomiting followed by generalized tonic-clonic seizures 3-4 episodes prior to admission.

Past history

Patient had past history of blood transfusions with 4 units of saline washed packed red cells, 4 weeks ago at an outside hospital in view of low hemoglobin (4 gm%). She was discharged on low dose oral corticosteroids.

On examination

She was afebrile with pulse rate of 100 beats/min regular, blood pressure was 190/110 mmHg in right arm, pallor was present and other general physical examination was normal. On admission, she was drowsy, pupils bilaterally equal and reacting to light, no neck stiffness and moving all four limbs. Fundus examination was normal. Cardiovascular, respiratory and abdominal examination was normal.

Management

During the course of hospital stay, patient landed up in status epilepticus, she received 4mg of iv diazepam followed by 1000mg of iv levetiracetam followed by phenytoin 1000mg. As seizures were not controlled, midazolam infusion was started at 15mg per hour with daily dosing of levetiracetam and phenytoin. Patient was intubated for airway protection and taken on volume control mode. After giving midazolam infusion, her seizures were controlled. In view of high blood pressure tablet amlodipine 10mg was given, blood pressure monitoring was done and thereafter there was no requirement of any anti-hypertensive medication. MRI Brain was done suggestive of multiple posterior periventricular and subcortical T2/FLAIR hyperintensities noted in bilateral occipital, high parietal and right cerebellar region appearing isointense on T1 showing no DWI restriction and blooming on GRE (Figure A and B).

Laboratory studies

Showed hemoglobin 11.4 gm/dl, WBC 4500 cells/mm³ (neutrophils- 58%), platelets 3 lakhs/cumm. Blood gas analysis showed pH-7.32, PO₂-78, PCO₂-38, and HCO₃⁻-22. Blood sugar was 134 mg/dl. Direct Coomb's test was positive. Serum electrolytes, liver function test, renal function test and urine analysis were normal. CSF showed 2 cells with 100% lymphocytes with normal protein and sugar. Blood, urine and endotracheal cultures were negative




Figure A: T2 W images showing hyperintense lesion in occipital and temporal lobe




Figure B: MRI images showing vasogenic oedema in occipital lobe

for any growth. Chest x-ray, ECG and 2D echocardiogram were also normal.

Therapeutic intervention

In view of classical clinical and radiological findings, PRES due to autoimmune hemolytic anemia was diagnosed. She was managed with supportive care- Antiepileptics, injection mannitol, antihypertensives along with once daily dose of prednisolone 40mg. She was discharged on oral supplementation of folic acid, zinc and vitamin B12.

DISCUSSION

Posterior reversible encephalopathy syndrome (PRES) was described first by Hinchey et al., in 1996.² Posterior reversible encephalopathy syndrome, also known as reversible posterior cerebral edema syndrome, reversible posterior leukoencephalopathy syndrome and reversible occipital parietal encephalopathy is a syndrome with heterogeneous etiologies and characteristic clinical and

radiological features.³ The characteristic clinical features and radiological criteria help in establishing the diagnosis of posterior reversible encephalopathy syndrome.^{4,5} The incidence of PRES is still unknown due to its heterogeneous presentation but the syndrome has female preponderance as it is more common in autoimmune conditions, preeclampsia, HELLP, etc.

The various etiologies leading to posterior reversible encephalopathy syndrome are heterogeneous and can be broadly classified as follows, Table 1.

PRES is marked by symptoms such as headache, seizures, impaired consciousness and hallucinations (visual). It is usually associated with acute rise in blood pressure. Headache is the most prevalent clinical presentation, accompanied by improvements in the consciousness, which can range from lethargy to coma and somnolence.

The pathophysiology of PRES is still unclear, but it is often seen in conditions with immune challenge leading to T-lymphocyte and/or endothelial activation. Leukocyte activation and vasoconstriction, both systemic and cerebral may cause faulty cerebral autoregulation. Because there are many etiologies, different mechanisms are proposed for different clinical situations. The proposed mechanisms are; A) As the upper limit of autoregulation is crossed arterioles

dilate allowing for hyper perfusion, causing breakdown of blood brain barrier. This leads to extravasation from vessels into the brain parenchyma.⁹ B) Endothelial dysfunction especially in cases preeclampsia and cytotoxic drug use is associated with toxicity to vascular endothelium causing blood brain barrier disruption, capillary leakage and axonal swelling. Vasogenic edema seen with therapies may be seen in normotensive individuals and with therapeutic levels of these drugs.²

Usually, PRES is identified based on characteristic clinical symptoms, neuroimaging (computed tomography or images of MRI).¹⁰ MRI is the gold standard and only 50% of the lesions were revealed by the CT scan.¹¹ In order to identify symptoms of cytotoxic oedema, which is a symptom of the progression of the disease, PRES clinicians should be aware of MRI findings in a suspected case.¹² In order to begin treatment and prevent death, a timely diagnosis is necessary.

The initial assessment of PRES patients should concentrate on rapid rectification of high blood pressure, the use of crystalloids for hydration and maintaining ample oxygenation. Aggressive management of underlying pathology and raised blood pressure is the usual treatment for neurological findings. Supportive treatment with fluids, analgesics, antiepileptics, etc and the prevention of possible causative factors is the line of management.¹³

Autoimmune hemolytic anemia is a moderately sporadic condition, estimated to be incidence of 1-3 cases per 100 000 per annum. In 48-70 percent of cases of AIHA, warm autoantibodies are responsible for destruction of RBC'S and consequent anemia.¹⁴ Hemolysis may be acute, chronic, episodic.

In our patient with autoimmune hemolytic anemia, PRES could have been precipitated by either, Table 2.

Table 1: Etiology of Posterior Reversible Encephalopathy Syndrome

General	Hypertension, sepsis and septic shock ⁶
Pregnancy associated	pre-eclampsia, HELLP syndrome ⁶
Autoimmune pathology	systemic sclerosis, polyarteritis nodosa Wegener's granulomatosis, Systemic lupus erythematosus Polyangitis ⁷
Immunosuppressive/ cytotoxic drugs	cyclosporine, tacrolimus, paclitaxel, oxaliplatin, cisplatin, gemcitabine, bevacizumab, sunitinib, sorafenib, etc ⁸

Table 2: Review of cases of PRES after blood transfusion

Sr.no	Age	Hb pre and post transfusion	Onset of PRES after transfusion (days)	Cause of anaemia	Sequelae	Reference
1.	45	2.0gm-10.0gm%	2	Myoma uteri	None	16
2.	48	3.0gm%-8.0gm%	6	Myoma uteri	None	17
3.	47	1.5gm%-10.9gm%	7	Aplastic anaemia	Visual defect	18
4.	58	7.7gm%-10.9gm%	8	Cancer surgery	None	19
5.	77	9.2gm%-13.3gm%	17	Cancer surgery	None	19
6.	32	5.7gm%-12.5gm%	5	Myoma uteri	None	20
7.	42	5.7gm%-11.7gm%	6	CKD, CLD*	None	21
8.	56	2.0gm%-9.2gm%	6	Corpus uteri	None	22
9.	35	3.5gm%**	10	Unsafe abortion	None	15
10 (Present case)	23	4.0-11.4 gm%	28	AIHA	None	

*Chronic Kidney Disease, Chronic Liver Disease

**Patient received 5 units transfusion due to Hb of 3.4gm% at a local hospital and also had on going blood loss

- a) Multiple blood transfusions causing activation of complement mediated (immune complex) activation of T cells/endothelial cells leading to PRES.
- b) Patient was on long term oral steroids, consumption of oral steroids for prolonged periods may lead to systemic hypertension. High blood pressure can precipitate PRES by causing cerebral vasoconstriction.
- c) The occurrence of PRES is thought to be caused by a rapid correction in the Haemoglobin levels and viscosity by blood transfusion.

Our patient's clinical findings suggest that severe cytotoxic oedema in the brain may have caused neurological manifestations. Furthermore, if anaemia is quickly reversed by blood transfusion, physicians should verify the existence of risk factors, including elevation of CRP levels, hypoalbuminemia, renal injury and female sex.

The rise in CRP levels could be associated with worsening of PRES by increasing the sensitivity of the blood-brain barrier to endothelial damage associated with inflammation. Hypoalbuminemia by decreasing colloid osmotic pressure affects the production of edema in PRES. Endothelial cell damage, which is a weak predictive marker, is reported to mediate renal injury. These factors can influence the incidence of PRES in patients with severe anaemia following transfusion of blood. However, in order to minimise the risk of this complication of the central nervous system, it would seem that in an environment of subacute to chronic anaemia, a gentler correction of haemoglobin over days is preferable as long as the patient is hemodynamically stable.

Review of literature

Till date only 9 cases of PRES associated with blood transfusion have been reported in literature, all of which were seen in female patients.¹⁵ Our patient had prior history of blood transfusion 28 days ago. The pathophysiology of transfusion related PRES has been discussed above.

CONCLUSION

Our case shows that PRES is associated with multiple blood transfusions. High suspicion index with clinical symptoms, early brain imaging, prompt diagnosis and treatment can decrease morbidity, mortality and promote early recovery.

REFERENCES

1. McKinney AM, Short J, Truwit CL, McKinney ZJ, Kozak OS, SantaCruz KS, et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. *American Journal of Roentgenology*. 2007; 189(4):904-912. <https://doi.org/10.2214/AJR.07.2024>
2. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. *New England Journal of Medicine*. 1996; 334(8):494-500. <https://doi.org/10.1056/NEJM199602223340803>
3. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. *American Journal of Neuroradiology*. 2008; 29(6):1036-1042. <https://doi.org/10.3174/ajnr.A0928>
4. Sweany JM, Bartynski WS and Boardman JF. "Recurrent" Posterior Reversible Encephalopathy Syndrome: Report of 3 Cases-PRES Can Strike Twice!. *Journal of computer assisted tomography*. 2007; 31(1):148-156. <https://doi.org/10.1097/01.rct.0000233127.21303.b9>
5. Sato Y, Ito T, Iguchi A, Yoshita K, Ito Y, Imai N, et al. Posterior reversible encephalopathy syndrome and microangiopathic haemolytic anaemia developing in a regularly haemodialysed patient with scleroderma renal crisis: a case report. *Modern Rheumatology Case Reports*. 2019; 3(2):124-129. <https://doi.org/10.1080/24725625.2018.1563325>
6. Rabinstein AA, Mandrekar J, Merrell R, Kozak OS, Durosaro O and Fugate JE. Blood pressure fluctuations in posterior reversible encephalopathy syndrome. *J Stroke Cerebrovasc Dis*. 2012; 21(4):254-258. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2011.03.011>
7. Gatla N, Annapureddy N, Sequeira W and Jolly M. Posterior reversible encephalopathy syndrome in systemic lupus erythematosus. *J Clin Rheumatol*. 2013; 19(6):334-340. <https://doi.org/10.1097/RHU.0b013e3182a21ffd>
8. Kou R, Greif D and Michel T. Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor. Implications for the vascular responses to cyclosporin A. *J Biol Chem*. 2002; 277(33):29669-29673. <https://doi.org/10.1074/jbc.M204519200>
9. Paulson OB, Strandgaard S and Edvinsson L. Cerebral autoregulation. *Cerebrovasc Brain Metab Rev*. 1990; 2(2):161-192.
10. Hu H, Xu S, Hu S, Xu W and Shui H. The clinical characteristics of posterior reversible encephalopathy syndrome in patients with chronic renal failure. *Experimental and Therapeutic Medicine*. 2017; 14(1):881-887. <https://doi.org/10.3892/etm.2017.4570>
11. Mirzamoradi M, Hosseini MS, Saleh M and Esmaeili S. Posterior reversible encephalopathy syndrome (PRES) associated with eclampsia: a case study. *International Journal of Medical Research and Health Sciences*. 2017; 6(3):48-53.
12. Marcocchia E, Piccioni MG, Schiavi MC, Colagiovanni V, Zannini I, Musella A, et al. Postpartum posterior reversible encephalopathy syndrome (PRES): Three case reports and literature review. *Case reports in obstetrics and gynecology*. 2019; 9527632. <https://doi.org/10.1155/2019/9527632>
13. Hobson EV, Craven I and Blank SC. Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness. *Perit Dial Int*. 2012; 32(6):590-594. <https://doi.org/10.3747/pdi.2012.00152>
14. Kaur P, Basu S, Kaur R and Kaur G. Immune Hemolytic Anemia: A report of two cases. *Journal of laboratory physicians*. 2009; 1(1):22. <https://doi.org/10.4103/0974-2727.54803>
15. Sudulagunta SR, Sodalagunta MB, Kumbhat M and Nataraju AS. Posterior reversible encephalopathy syndrome(PRES). *Oxford Medical Case Reports*. 2017; 2017(4). <https://doi.org/10.1093/omcr/omx011>

16. Ito Y, Niwa H, Iida T, Nagamatsu M, Yasuda T, Yanagi T, et al. Post-transfusion reversible posterior leukoencephalopathy syndrome with cerebral vasoconstriction. *Neurology*. 1997; 49(4):1174-1175.
<https://doi.org/10.1212/WNL.49.4.1174>
17. Boughammoura A, Touz E, Oppenheim C, Trystram D and Mas JL. Reversible angiopathy and encephalopathy after blood transfusion. *Journal of Neurology*. 2003; 250(1):116-118.
<https://doi.org/10.1007/s00415-003-0940-4>
18. Heo K, Park SA, Lee JY, Lee BI and Lee SK. Post-Transfusion Posterior Leukoencephalopathy with Cytotoxic and Vasogenic Edema Precipitated by Vasospasm. *Cerebrovascular Diseases*. 2003; 15(3):230-233.
<https://doi.org/10.1159/000068825>
19. Kawano H, Suga T, Terasaki T, Hashimoto Y, Baba K and Uchino M. [Posterior encephalopathy syndrome in two patients after cancer surgery with transfusion]. *Rinsho Shinkeigaku*. 2004; 44(7):427-431. Japanese.
20. Huang YC, Tsai PL, Yeh JH and Chen WH. Reversible posterior leukoencephalopathy syndrome caused by blood transfusion: a case report. *Acta Neurol Taiwan*. 2008; 17:258-262.
21. Sato Y, Hirose M, Inoue Y, Komukai D, Takayasu M, Kawashima E, et al. Reversible posterior leukoencephalopathy syndrome after blood transfusion in a patient with end-stage renal disease. *Clin Exp Nephrol*. 2011; 15:942-947.
<https://doi.org/10.1007/s10157-011-0515-0>
22. Wada KI, Kano M, Machida Y, Hattori N and Miwa H. Posterior reversible encephalopathy syndrome induced after blood transfusion for severe anemia. *Case Rep Clin Med*. 2013; 2:332.
<https://doi.org/10.4236/crcm.2013.25089>

Author's contribution:

SD-Concept, coordination, review of literature and manuscript preparation; **SG**-Concept, prepared first draft of manuscript; **AS**-Reviewed the literature and manuscript preparation; **SA**- Coordination, preparation of manuscript and revision of the manuscript.

Work attributed to:

Acharya Vinoba Bhave Rural Hospital, Wardha, Maharashtra.

Orcid ID:

Dr. Sameera Dronamraju- <https://orcid.org/0000-0002-6755-3916>

Dr. Shilpa Gaidhane- <https://orcid.org/0000-0002-3012-7438>

Dr. Ayush Somani- <https://orcid.org/0000-0001-8083-7879>

Dr. Sourya Acharya- <https://orcid.org/0000-0003-1969-0817>

Consent of the patient was asked and received

Source of Funding: Nil, **Conflict of Interest:** None declared.